J.B. Chemicals & Pharmaceuticals Limited (JBCPL), a pharmaceutical company in India, announced that it will acquire brands for the India market from Sanzyme Private Limited (Sanzyme), a leading player in the probiotics and reproductive health segment in the country. The transaction is valued at INR ~ 628 crore and is expected to be completed in…
Cipla Limited and Boehringer Ingelheim India Pvt. Ltd. (BI) announced that they have entered into a partnership to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India. As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes,…
Cipla Limited and Roche Products (India) Pvt. Ltd. announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. As part of the agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs viz.,Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab…
Cipla Ltd. announced the acquisition of nutrition products’ portfolio from Wanbury Ltd. Cipla has acquired 4 brands — CPink, CDense, Productiv and Folinine to further strengthen its presence in women’s health. The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or…
Cipla Ltd. has acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin + Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India…